Last reviewed · How we verify
Talc Slurry Pleurodesis
Talc slurry induces chemical pleurodesis by causing inflammation and fibrosis of the pleural surfaces, obliterating the pleural space to prevent fluid reaccumulation.
Talc slurry induces chemical pleurodesis by causing inflammation and fibrosis of the pleural surfaces, obliterating the pleural space to prevent fluid reaccumulation. Used for Recurrent malignant pleural effusion, Recurrent benign pleural effusion (pneumothorax, heart failure).
At a glance
| Generic name | Talc Slurry Pleurodesis |
|---|---|
| Also known as | TSP |
| Sponsor | Memorial Healthcare System |
| Drug class | Sclerosing agent |
| Modality | Small molecule |
| Therapeutic area | Oncology / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
When instilled into the pleural cavity, talc particles trigger an inflammatory response that leads to adhesion and fusion of the visceral and parietal pleura. This obliteration of the pleural space prevents the reaccumulation of pleural effusion, providing long-term control of recurrent malignant or benign pleural effusions. The mechanism is primarily physical and inflammatory rather than pharmacological.
Approved indications
- Recurrent malignant pleural effusion
- Recurrent benign pleural effusion (pneumothorax, heart failure)
Common side effects
- Chest pain
- Fever
- Dyspnea
- Acute respiratory distress syndrome (ARDS)
- Empyema
- Hypoxemia
Key clinical trials
- Comparison of Talc Slurry Versus Talc Insufflation: A Study on Effectiveness, Safety, and Hospital Outcomes in Pleurodesis (NA)
- Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis (PHASE4)
- Stop Air Leak by Talc or Autologous Blood Patch Therapy (PHASE2, PHASE3)
- Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management (NA)
- Efficacy, Safety and Re-occurrence of Pneumothorax and Hydro-pneumothorax With Talc and Pyodine Pleurodesis (PHASE1, PHASE2)
- Talc Outpatient Pleurodesis With Indwelling Catheter (NA)
- Using Ultrasound to Predict the Results of Draining Pleural Effusions
- EDIT Management Feasibility Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Talc Slurry Pleurodesis CI brief — competitive landscape report
- Talc Slurry Pleurodesis updates RSS · CI watch RSS
- Memorial Healthcare System portfolio CI